文献速递血脂与心血管预防

非诺贝特治疗与他汀治疗的2型糖尿病患者长期心血管风险的关联

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
PubMed 文献 · JAMA Cardiol · 2017-01-01

ACCORD脂质研究的事后随访(2009年7月至2014年10月,中位总随访9.7年)显示,在4644例他汀治疗的2型糖尿病患者中,最初随机接受非诺贝特与安慰剂者的主要复合心血管结局风险相当(HR 0.93,95%CI 0.83-1.05,P=0.25);在甘油三酯大于204 mg/dL且高密度脂蛋白胆固醇小于34 mg/dL的亚组中,非诺贝特与心血管病风险降低相关(HR 0.73,95%CI 0.56-0.95)。

要点

  • 总体队列中非诺贝特与安慰剂的主要心血管结局风险无显著差异(HR 0.93,95%CI 0.83-1.05)。
  • 甘油三酯大于204 mg/dL且高密度脂蛋白胆固醇小于34 mg/dL者,非诺贝特与心血管病风险降低相关(HR 0.73)。
  • 作者认为该患者人群需开展决定性试验以确认这些发现。

核心结论

  • ACCORD脂质试验参与者的延长随访证实非诺贝特在整个研究队列中的中性效应。
  • 基线血脂提示的治疗反应异质性持续存在,提示非诺贝特可能降低伴高甘油三酯血症和低高密度脂蛋白胆固醇的糖尿病患者的心血管病风险。
  • 作者认为该患者人群需开展决定性试验以确认这些发现。

研究设计与样本

  • ACCORD脂质研究的事后随访,2009年7月至2014年10月,完成5年随访,总随访达9.7年,在美国和加拿大的社区和学术门诊研究诊所进行。
  • 从原5518例ACCORD脂质试验参与者中选取4644例存活参与者,入选基于2型糖尿病以及存在心血管病或心血管病危险因素且高密度脂蛋白水平小于50 mg/dL(女性和非裔美国人为小于55 mg/dL)。
  • 对既往接受非诺贝特或盲法安慰剂治疗的参与者进行被动随访。

主要发现

  • 4644例随访参与者中女性1445例(31%),非白人1094例(21%),既往有心血管事件者1620例(35%)。
  • 仅4.3%的研究参与者在ACCORD完成后继续接受非诺贝特治疗。
  • 最初随机接受非诺贝特或安慰剂的参与者之间高密度脂蛋白和甘油三酯值迅速均衡。
  • 在甘油三酯大于204 mg/dL且高密度脂蛋白胆固醇小于34 mg/dL的亚组中,非诺贝特与心血管病风险降低相关(HR 0.73;95%CI 0.56-0.95)。

关键数值与推荐

  • 血脂异常定义为甘油三酯大于204 mg/dL且高密度脂蛋白胆固醇小于34 mg/dL,该亚组中非诺贝特 vs 安慰剂的心血管病风险 HR 0.73(95%CI 0.56-0.95)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol. It is unknown whether adding triglyceride-lowering treatment to statin reduces this risk. OBJECTIVE: To determine whether fenofibrate reduces CVD risk in statin-treated patients with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Posttrial follow-up of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study between July 2009 and October 2014; 5 years of follow-up were completed for a total of 9.7 years at general community and academic outpatient research clinics in the United States and Canada. Of the original 5518 ACCORD Lipid Trial participants, 4644 surviving participants were selected based on the presence of type 2 diabetes and either prevalent CVD or CVD risk factors and high-density lipoprotein levels less than 50 mg/dL (<55 mg/dL for women and African American individuals). INTERVENTIONS: Passive follow-up of study participants previously treated with fenofibrate or masked placebo. MAIN OUTCOMES AND MEASURES: Occurrence of cardiovascular outcomes including primary composite outcome of fatal and nonfatal myocardial infarction and stroke in all participants and in prespecified subgroups. RESULTS: The 4644 follow-on study participants were broadly representative of the original ACCORD study population and included significant numbers of women (n = 1445; 31%), nonwhite individuals (n = 1094; 21%), and those with preexisting cardiovascular events (n = 1620; 35%). Only 4.3% of study participants continued treatment with fenofibrate following completion of ACCORD. High-density lipoprotein and triglyceride values rapidly equalized among participants originally randomized to fenofibrate or placebo. Over a median total postrandomization follow-up of 9.7 years, the hazard ratio (HR) for the primary study outcome among participants originally randomized to fenofibrate vs placebo (HR, 0.93; 95% CI, 0.83-1.05; P = .25) was comparable with that originally observed in ACCORD (HR, 0.92; 95% CI, 0.79-1,08; P = .32). Despite these overall neutral results, we continued to find evidence that fenofibrate therapy effectively reduced CVD in study participants with dyslipidemia, defined as triglyceride levels greater than 204 mg/dL and high-density lipoprotein cholesterol levels less than 34 mg/dL (HR, 0.73; 95% CI, 0.56-0.95). CONCLUSIONS AND RELEVANCE: Extended follow-up of ACCORD-lipid trial participants confirms the original neutral effect of fenofibrate in the overall study cohort. The continued observation of heterogeneity of treatment response by baseline lipids suggests that fenofibrate therapy may reduce CVD in patients with diabetes with hypertriglyceridemia and low high-density lipoprotein cholesterol. A definitive trial of fibrate therapy in this patient population is needed to confirm these findings. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00000620.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Elam MB, Ginsberg HN, Lovato LC, et al. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiol. 2017. PMID: 28030716. doi:10.1001/jamacardio.2016.4828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。